Yahoo Finance [Yahoo! Finance]
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Yahoo! Finance
Jefferies initiated a "buy" rating on Rocket Pharmaceuticals based on the biotech firm's experimental gene therapies. Jefferies also set a price target of $29. The analysts said they were especially optimistic about Rocket's treatment for a rare genetic heart condition, which they believe could be a $1 billion opportunity for the company. Shares of Rocket Pharmaceuticals ( RCKT ) jumped 5.5% intraday Wednesday as Jefferies initiated coverage of the biotech company with a "buy" rating on optimism about the experimental drugs in its pipeline. Jefferies also set a price target of $29, more than double its current value. The analysts wrote in a note to clients that Rocket Pharma is testing five or more gene therapy treatments for rare diseases. They were especially focused on RP-A501 (AAV9) for Danon heart disease, a genetic disorder that affects the heart with no current treatment options. The analysts explained that the medicine "has a high 65-75% chance to succeed in a pivot
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $29.00 price target on the stock.MarketBeat
- Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockBusiness Wire
- Rocket Pharmaceuticals Announces Proposed Public Offering of Common StockBusiness Wire
- Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain [Seeking Alpha]Seeking Alpha
RCKT
Earnings
- 11/7/24 - Beat
RCKT
Sec Filings
- 12/16/24 - Form SC
- 12/16/24 - Form 4
- 12/12/24 - Form 8-K
- RCKT's page on the SEC website